This company has been marked as potentially delisted and may not be actively trading. resTORbio (TORC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TORC vs. GNLX, COYA, SGMT, MGNX, CTNM, OPTN, IMUX, ASMB, ZNTL, and ORMPShould you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Genelux (GNLX), Coya Therapeutics (COYA), Sagimet Biosciences (SGMT), MacroGenics (MGNX), Contineum Therapeutics (CTNM), OptiNose (OPTN), Immunic (IMUX), Assembly Biosciences (ASMB), Zentalis Pharmaceuticals (ZNTL), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "medical" sector. resTORbio vs. Genelux Coya Therapeutics Sagimet Biosciences MacroGenics Contineum Therapeutics OptiNose Immunic Assembly Biosciences Zentalis Pharmaceuticals Oramed Pharmaceuticals Genelux (NASDAQ:GNLX) and resTORbio (NASDAQ:TORC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation, profitability and community ranking. Does the MarketBeat Community prefer GNLX or TORC? resTORbio received 124 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 67.14% of users gave resTORbio an outperform vote. CompanyUnderperformOutperformGeneluxOutperform Votes17100.00% Underperform VotesNo VotesresTORbioOutperform Votes14167.14% Underperform Votes6932.86% Does the media prefer GNLX or TORC? In the previous week, Genelux's average media sentiment score of 0.00 equaled resTORbio'saverage media sentiment score. Company Overall Sentiment Genelux Neutral resTORbio Neutral Do insiders & institutionals have more ownership in GNLX or TORC? 37.3% of Genelux shares are held by institutional investors. Comparatively, 46.2% of resTORbio shares are held by institutional investors. 9.3% of Genelux shares are held by insiders. Comparatively, 11.8% of resTORbio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, GNLX or TORC? Genelux has higher revenue and earnings than resTORbio. Genelux is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$8K11,745.02-$28.30M-$0.88-2.83resTORbioN/AN/A-$82.74M-$2.41-0.29 Do analysts prefer GNLX or TORC? Genelux presently has a consensus target price of $17.75, indicating a potential upside of 612.85%. Given Genelux's stronger consensus rating and higher probable upside, equities research analysts plainly believe Genelux is more favorable than resTORbio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20resTORbio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GNLX or TORC more profitable? resTORbio's return on equity of -78.12% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -105.05% -80.16% resTORbio N/A -78.12%-71.63% Which has more risk & volatility, GNLX or TORC? Genelux has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500. Comparatively, resTORbio has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500. SummaryGenelux beats resTORbio on 8 of the 15 factors compared between the two stocks. Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TORC vs. The Competition Export to ExcelMetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.52M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.399.0626.7119.71Price / SalesN/A251.48386.12120.59Price / CashN/A65.8538.2534.62Price / Book0.316.456.774.50Net Income-$82.74M$143.98M$3.23B$248.22M resTORbio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TORCresTORbioN/A$0.70-6.6%N/A-53.7%$25.52MN/A-0.39N/AGap DownGNLXGenelux1.2154 of 5 stars$2.78-6.1%$17.75+538.5%-50.4%$104.90M$8,000.00-2.9310High Trading VolumeCOYACoya Therapeutics2.0983 of 5 stars$6.14+1.5%$17.00+176.9%-31.7%$102.69M$3.55M-9.456News CoverageAnalyst DowngradeAnalyst RevisionGap UpSGMTSagimet Biosciences1.5921 of 5 stars$3.31+1.5%$22.40+576.7%-32.8%$101.53M$2M-2.318MGNXMacroGenics3.5559 of 5 stars$1.59+11.2%$7.43+367.2%-65.0%$100.31M$148.34M-1.01430News CoverageAnalyst ForecastAnalyst RevisionCTNMContineum Therapeutics2.2055 of 5 stars$3.83-1.0%$23.75+520.1%-75.9%$99.09M$50M-0.7831Analyst ForecastOPTNOptiNose3.1823 of 5 stars$9.42+0.3%$9.00-4.5%-44.4%$95.09M$78.23M-2.24190News CoverageAnalyst ForecastAnalyst RevisionIMUXImmunic2.418 of 5 stars$0.99-2.3%$13.20+1,237.8%-27.6%$94.54MN/A-0.8070Earnings ReportASMBAssembly Biosciences3.5868 of 5 stars$12.35+0.9%$33.00+167.2%-10.4%$94.33M$28.52M-1.98100Positive NewsZNTLZentalis Pharmaceuticals2.0976 of 5 stars$1.29+4.9%$8.24+539.1%-89.6%$92.82M$67.43M-0.52160Analyst RevisionORMPOramed Pharmaceuticals1.8064 of 5 stars$2.24-0.4%N/A-8.7%$91.50M$1.34M20.3610Earnings Report Related Companies and Tools Related Companies Genelux Alternatives Coya Therapeutics Alternatives Sagimet Biosciences Alternatives MacroGenics Alternatives Contineum Therapeutics Alternatives OptiNose Alternatives Immunic Alternatives Assembly Biosciences Alternatives Zentalis Pharmaceuticals Alternatives Oramed Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TORC) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
